Skip to main content
IN THE KNOW

Resources.

TOPICS

Client news
MedImpact leverages advanced technology and network solutions to improve member experience and reduce costs for our pharmacy partners.
The U.S. spends more per capita on healthcare than any other country in the world, but it has a high prevalence of diabetes, worse cardiovascular outcomes and lower life expectancy compared to other high-income countries.1 U.S. healthcare costs reached $3.6 trillion in 2018 and spending is anticipated to soar to nearly $6 trillion by 2027.2 However, the U.S. ranks poorly in health system performance.3
READ MORE
Client news
NY Attorney General recognizes MedImpact for assisting in multimillion dollar medicaid FWA investigation.
Fraud, waste, and abuse (FWA) is a national crisis that costs our healthcare system at least $200 billion every year. Even worse, research suggests that only a mere 5% of these losses are recovered.1
READ MORE
Client news
The hazards of auto-refills.
MedImpact helps reduce waste and oversupply with flexible auto-refill strategies.
READ MORE
Client news
Annual drug trend report looks at Medicare brand and generic drug trends.
Breaking news of the White House’s consideration of a sweeping executive order that could cut prices on brand-name prescription drugs sold to Medicare and other government programs continues to top this week’s healthcare headlines.
READ MORE
Client news
Investigating top diabetes trends by lines of business.
Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.
READ MORE
Client news
MedImpact investigates the impact of oral semaglutide and diabetes market trends.
With the potential to change the landscape of diabetes treatment, oral semaglutide ushers in the next generation of diabetes care with its anticipated FDA approval in September.
READ MORE
Client news
Can you put a price on life?
FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.
READ MORE
Client news
FDA approves first and only treatment for common mutation in advanced breast cancer.
The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.
READ MORE
Client news
Dispelling the myth: generics are not always low cost.
When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know:
READ MORE
We are the PBM that puts clients and consumers first. Always. Ready for a change?